斯蒂格马斯特通过抑制JAK3减弱了三阴性乳腺癌干细胞的特性
Ruijuan Zhou1, Yuzhu Zhang2, Leqin Xu1
1Department of Chest and Breast Surgery, Xiamen Hospital of Traditional Chinese Medicine, Fujian University of Traditional Chinese Medicine, Xiamen, China.
Journal of Cancer
|February 24, 2025
概括
斯蒂格马斯特通过降低JAK3.3的调节来抑制乳腺癌干细胞 (BCSCs) 的发生. 这种天然化合物抑制了BCSCs.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 乳腺癌类似干细胞 (BCSCs) 驱动瘤发作,转移和耐药性,阻碍有效治疗.
- 斯蒂格马斯托尔对抗癌症过程的潜力是已知的,但它对BCSCs的特定作用和机制仍未被探索.
研究的目的:
- 调查青醇对乳腺癌类干细胞 (BCSCs) 的作用和潜在机制.
- 评价污醇对BCSC细胞干,转移和耐药性的影响.
主要方法:
- 用无血清介质用BCSCs丰富父细胞和SUM159细胞,以形成球形.
- 在体外和体内实验,以评估对BCSC的干性,迁移,亡和瘤产生的影响.
- 在BCSC中对Janus Kinase 3 (JAK3) 表达的分析,以及由stigmasterol对其的调节.
主要成果:
- 斯蒂格马斯特抑制了BCSCs的球形形成,活力,迁移和瘤发生,同时促进了亡.
- 斯蒂格马斯特抑制了三阴性乳腺癌 (TNBC) 器官的生长.
- 发现JAK3在BCSC上升调节,而污名醇抑制了它的表达,从而抑制了BCSC的活动.
结论:
- 这项研究表明,通过对JAK3的降低调节,树脂醇对BCSC的干部和转移有抑制作用.
- 斯蒂格马斯托尔通过通过JAK3抑制向BCSCs,为乳腺癌提供了潜在的治疗策略.
相关概念视频
01:20The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
02:40Cancer Stem Cells and Tumor Maintenance
4.7K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.7K
01:19Mesenchymal Stem Cells
4.6K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.6K
01:26Stem Cell Niche
5.0K
The stem cell niche is the dynamic microenvironment where stem cells reside. Inside these niches, the cells may remain undifferentiated, undergo high self-renewal, or become lineage-specific progenitors. Stem cells coexist with other niche cells, such as stromal cells. They also interact closely with the ECM. Cell-cell and cell-matrix communication occur via adhesion molecules or soluble factors that signal the stem cells and determine their fate. Stromal cells also provide survival signals to...
5.0K